Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
Alla chiusura: 04:00PM EST
Dopo ore:
| Chiusura precedente | 74,88 |
| Aperto | 75,71 |
| Denaro | 0,00 x 800 |
| Lettera | 0,00 x 800 |
| Min-Max giorno | 74,47 - 76,30 |
| Intervallo di 52 settimane | 61,91 - 101,47 |
| Volume | |
| Media Volume | 2.262.503 |
| Capitalizzazione | 16,569B |
| Beta (5 anni mensile) | 0,73 |
| Rapporto PE (ttm) | 31,10 |
| EPS (ttm) | 2,41 |
| Prossima data utili | 08 feb 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 92,38 |
- GlobeNewswire
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreeme
© 2022 Yahoo. Tutti i diritti riservati.
